Impact on Publicly Traded Bio/Pharma Companies - Coronavirus Disease (COVID-19) 2019 Impact Report

Market: Pharmaceuticals and Healthcare

Global, 34 pages report, published by GlobalData

Report ThumbnailJune-2020
Impact on Publicly Traded Bio/Pharma Companies - Coronavirus Disease (COVID-19) 2019 Impact Report

Summary

The Coronavirus (COVID-19) company impact report analyses how the pandemic has impact the top 20 Mega Cap Bio/Pharma Companies revenue, future revenue, and market capitalization.

Scope

- This report gives an important expert analysis on how COVID-19 has affected, and will continue to affect, the top 20 Mega Cap Bio/Pharma Companies. Findings are based on the industry’s most comprehensiv

Read More
  • Table of Contents
  • 1. Market Cap Change for Bio/Pharma Companies in Q1 2020
  • Market Cap for Bio/Pharma Companies With and Without a COVID-19 Drug over Q1 2020
  • Q1 2020 Change in Market Cap by Company Market Cap Size
  • 2. Market Cap for Top 20 Bio/Pharma Companies: Q1 2020 vs. 2019
  • Market Cap Change for Top 20 Bio/Pharma: Q1 2020 vs. 2019
  • Market Cap Change Q1 2020: Bayer AG
  • Market Cap Change Q1 2020: Gilead Sciences
  • Market Cap Change Q1 2020: Regeneron Pharmaceuticals
  • Q1 2020 Market Cap Change for Top
Read More

Please select a license type

Share

Related Products

GlobalDataImpact on Publicly Traded Bio/Pharma Companies - Coronavirus Disease (COVID-19) 2019 Impact ReportProduct ThumbnailImpact on Publicly Traded Bio/Pharma Companies - Coronavirus Disease (COVID-19) 2019 Impact Report, Industry ReportProduct #: 1218497
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2021 Global Market Analyst. All Rights Reserved